Can I Take Saw Palmetto with Jardiance (Empagliflozin)?

How Jardiance (Empagliflozin) Works

Empagliflozin blocks the sodium-glucose co-transporter 2 (SGLT2) protein in the proximal renal tubule, causing the kidneys to excrete roughly 70 grams of glucose into the urine per day in patients with type 2 diabetes. [1] That mechanism lowers hemoglobin A1c by approximately 0.5 to 1.0 percentage points and body weight by 2 to 3 kg on the 25 mg dose over 24 weeks. [2]

Beyond glucose control, empagliflozin demonstrated in the EMPA-REG OUTCOME trial (N=7,020) a 38% relative risk reduction in cardiovascular death versus placebo in adults with type 2 diabetes and established cardiovascular disease. [3] The EMPEROR-Reduced trial (N=3,730) extended that benefit to patients with heart failure with reduced ejection fraction (HFrEF), showing a 25% reduction in the composite of cardiovascular death or heart failure hospitalization. [4]

Metabolism and Excretion

Empagliflozin is primarily metabolized by UGT1A3, UGT1A8, UGT1A9, and UGT2B7 via glucuronidation, not by cytochrome P450 enzymes. [1] This is a key pharmacokinetic fact: because CYP3A4, CYP2D6, and related isoforms are not involved, CYP-inhibiting or CYP-inducing supplements generally do not alter empagliflozin blood levels in a clinically meaningful way.

Renal excretion handles about 54% of the administered dose; fecal excretion accounts for 41%. [1] Half-life is approximately 12.4 hours, which supports once-daily dosing before the first meal.

Key Side Effects to Know Before Adding Any Supplement

• Genital mycotic infections (8.3% women, 3.1% men in phase 3 trials) [2]
• Urinary tract infections (approximately 9% incidence) [2]
• Volume depletion and modest blood pressure reduction (systolic BP drop of 3 to 5 mmHg) [2]
• Rare but serious: diabetic ketoacidosis (euglycemic), Fournier's gangrene, lower-limb amputation signal seen with canagliflozin (FDA class warning applies across SGLT2 class) [5]

Any supplement that independently affects volume status, kidney function, or platelet activity deserves scrutiny in this context.

What Is Saw Palmetto and Why Do People Take It?

Saw palmetto is a lipophilic extract from the berries of Serenoa repens, a fan palm native to the southeastern United States. The most studied indication is benign prostatic hyperplasia (BPH): roughly 2.5 million American men use it annually for lower urinary tract symptoms. [6]

Proposed Mechanisms

The extract contains free fatty acids and sterols that weakly inhibit both isoforms of 5-alpha-reductase (5-AR), the enzyme that converts testosterone to dihydrotestosterone (DHT). Reduced DHT in prostate tissue is hypothesized to shrink glandular volume over months. Saw palmetto also inhibits alpha-1 adrenergic receptors at the bladder neck in vitro, which may relax smooth muscle and improve urine flow.

The clinical evidence for BPH, however, is weaker than supplement marketing suggests. The STEP trial (N=225, 72 weeks) found no statistically significant difference between saw palmetto 320 mg daily and placebo on the American Urological Association Symptom Index. [7] A subsequent dose-escalation study using up to 960 mg daily found similar null results. [8]

Anticoagulant and Antiplatelet Properties

This is the pharmacodynamic property most relevant to people on Jardiance. In vitro and case-report literature documents that saw palmetto extracts inhibit platelet aggregation, possibly through thromboxane B2 pathway suppression. [9] At least three published case reports describe perioperative bleeding attributable to saw palmetto, leading major anesthesia societies to recommend stopping it 2 weeks before elective surgery. [10]

Saw palmetto does not appear on the FDA's formal list of drug-interaction contraindications, but the Natural Medicines Comprehensive Database assigns it a possible interaction rating with antiplatelet and anticoagulant drugs.

Effect on Hormone Pathways

Saw palmetto's 5-AR inhibition is considerably weaker than prescription finasteride (Proscar) or dutasteride (Avodart). Because empagliflozin's mechanism of action is entirely renal and does not involve androgen signaling, saw palmetto's hormonal activity should not interfere with Jardiance's glucose-lowering or cardioprotective effects.

Pharmacokinetic Interaction: Is There One?

The short answer is almost certainly no, based on what is known about each compound's metabolic pathway.

Empagliflozin is glucuronidated by UGT enzymes, not oxidized by CYP450. Saw palmetto's active constituents (oleic acid, lauric acid, beta-sitosterol, and related fatty acids) are absorbed and metabolized through lipid pathways, primarily intestinal esterases and hepatic lipid oxidation. [9] Neither compound is a known inhibitor or inducer of the UGT isoforms that clear empagliflozin.

CYP450 Overlap

In the HealthRX clinical pharmacy review of saw palmetto's in vitro inhibitory constants (Ki), no clinically relevant inhibition of UGT1A9 was identified at therapeutic concentrations of the extract. [6] This aligns with the absence of any pharmacokinetic case reports in the published literature pairing these two agents.

The table below summarizes how the two agents compare metabolically.

| Property | Empagliflozin | Saw Palmetto | |---|---|---| | Primary metabolism | UGT1A3, 1A8, 1A9, 2B7 (glucuronidation) | Intestinal esterases, hepatic lipid oxidation | | CYP450 involvement | Minimal (not CYP3A4/2D6 substrate) | Weak CYP2C9 inhibition in vitro only | | Renal clearance | 54% | Negligible | | Plasma protein binding | 86% | High (lipophilic, binds albumin/lipoproteins) | | Drug-drug PK interaction | Not expected | Not expected with empagliflozin |

No dose adjustment of empagliflozin is required based on saw palmetto co-administration from a pharmacokinetic standpoint.

Pharmacodynamic Interaction: The Real Concern

Even when two agents don't share a metabolic pathway, they can still produce additive or opposing effects in the body.

Bleeding Risk

Empagliflozin itself does not directly thin the blood. But many patients on Jardiance also take low-dose aspirin (81 mg), clopidogrel, or anticoagulants such as apixaban or rivaroxaban for cardiovascular protection, given the patient population EMPA-REG OUTCOME enrolled. Adding saw palmetto's antiplatelet activity on top of aspirin or a direct oral anticoagulant (DOAC) could push bleeding risk higher. The risk is not theoretical: the American Society of Anesthesiologists includes saw palmetto in its list of supplements requiring preoperative discontinuation specifically because of documented bleeding events. [10]

If you are on Jardiance plus aspirin or any DOAC, adding saw palmetto means three agents with antiplatelet or anticoagulant properties may be active simultaneously. Your prescriber should know before you start.

Volume Depletion Consideration

Empagliflozin causes osmotic diuresis. Patients who are volume-depleted are more sensitive to blood pressure drops. Saw palmetto does not appear to cause meaningful diuresis or volume loss on its own, so this combination does not carry a documented additive volume depletion risk. Still, any supplement in a patient with borderline blood pressure or renal function merits a conversation.

Urinary Tract Infection Risk

Empagliflozin increases glucosuria, which can feed bacterial and fungal growth in the genitourinary tract. Saw palmetto is often marketed for urinary health in men with BPH, but the clinical evidence that it reduces infection risk is absent. The STEP trial found no meaningful benefit on infection-related endpoints. [7] Do not assume saw palmetto provides any protective offset to Jardiance's UTI liability.

Kidney Function

Empagliflozin lowers intraglomerular pressure through tubuloglomerular feedback, which produces an expected early dip in estimated glomerular filtration rate (eGFR) of 3 to 5 mL/min/1.73 m2 before long-term nephroprotection becomes apparent. [11] The CREDENCE trial (N=4,401, canagliflozin) and DAPA-CKD trial (N=4,304, dapagliflozin) both confirmed this class-wide renoprotective pattern. Saw palmetto has no established effect on eGFR at typical doses, so no additive kidney concern has been identified.

What the Guidelines Say About Herb-Drug Interactions in Diabetes

The American Diabetes Association's Standards of Care (2024 edition) states: "Clinicians should ask patients about the use of complementary and alternative medicines, including herbal products, because of the potential for interactions with prescribed medications and the risk of adverse effects." [12] The ADA does not specifically address saw palmetto but emphasizes that the prescriber must be informed.

The Endocrine Society's clinical practice guideline on type 2 diabetes management echoes this position, noting that patients frequently underreport supplement use and that the absence of a known interaction does not equal confirmed safety. [13]

"Many patients assume that because something is 'natural,' it is automatically safe to combine with prescription drugs," said no specific individual, but this sentiment is widely attributed across ADA and Endocrine Society patient education materials. The evidence gap is real: fewer than 15% of herbal products sold in the U.S. Have been evaluated for interactions with SGLT2 inhibitors in any formal pharmacokinetic study.

Who Is Most at Risk When Combining These Two Agents?

Not all Jardiance patients face the same level of concern. Risk stratification helps prioritize who needs an urgent prescriber conversation versus who needs routine disclosure.

Higher-Risk Patient Profile

• Men over 65 using saw palmetto for BPH who are also on aspirin 81 mg or a DOAC for atrial fibrillation or post-MI protection
• Patients with eGFR between 20 and 45 mL/min/1.73 m2 where any additional insult to renal or vascular hemostasis is amplified
• Patients scheduled for surgery or an invasive dental procedure within 4 weeks

Lower-Risk Patient Profile

• Adults under 60 without cardiovascular disease using Jardiance solely for glycemic control, not on any antiplatelet agent, and taking saw palmetto at the standard 320 mg daily dose

Even in the lower-risk group, disclosure to a pharmacist takes about 90 seconds and costs nothing.

Practical Steps If You Are Already Taking Both

If you started saw palmetto before your Jardiance prescription, or vice versa, here is what to do.

Step 1: Tell Your Prescriber and Pharmacist Today

Provide the exact brand, dose, and duration of saw palmetto use. Many electronic health record drug-interaction checkers do not flag saw palmetto by default because it is a supplement, not a prescription drug. The disclosure must come from you.

Step 2: Review Your Full Medication List for Bleeding Risk

If your current regimen already includes aspirin, clopidogrel, warfarin, apixaban, rivaroxaban, edoxaban, or any NSAID used regularly, ask your prescriber directly whether stopping saw palmetto is advisable.

Step 3: Ask About Prescription Alternatives for BPH

If you are taking saw palmetto for BPH and your prescriber agrees the herbal supplement poses risk in your specific case, prescription options include tamsulosin (an alpha-blocker with no known interaction with empagliflozin) or finasteride 5 mg, which carries a well-characterized safety profile. These would replace, not add to, your current regimen.

Step 4: Monitor as Directed

Patients on Jardiance should already be receiving periodic monitoring of: basic metabolic panel (BMP) including creatinine and electrolytes, urinalysis, and hemoglobin A1c every 3 months until stable. [12] There is no specific additional lab test required solely because of saw palmetto co-use, but report any unusual bruising, prolonged bleeding from cuts, or new urinary symptoms to your care team promptly.

Evidence Quality and Gaps

The interaction literature between saw palmetto and any SGLT2 inhibitor is sparse. A 2023 PubMed search combining "saw palmetto" with "empagliflozin," "dapagliflozin," or "canagliflozin" returns zero controlled trials and fewer than five relevant case reports or mechanistic papers. [6, 9]

That absence of evidence is not evidence of absence of harm. It reflects the general under-study of supplement-drug combinations rather than a clean bill of safety. The Cochrane systematic review on saw palmetto for BPH (2023 update, 32 trials, N=5,666) focused on efficacy endpoints and did not evaluate interactions with prescription medications. [14]

Given this gap, the HealthRX medical team rates the overall interaction concern as low-to-moderate, driven primarily by the bleeding signal rather than pharmacokinetic overlap. Patients with cardiovascular comorbidities and concurrent antithrombotic therapy should treat this as a moderate concern requiring explicit prescriber input.

The current evidence base supports a 2-week washout of saw palmetto before any planned surgery or invasive procedure in a Jardiance patient, consistent with established anesthesia guidance. [10]